Pharmaceutical company intelligence reports from Espicom provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events. Biogen Idec is a global research-based company focused on the development, manufacture and commercialisation of novel therapeutics for human health care. Biogen Idec's headquarters in Cambridge, MA, is strategically close to the renowned research institutions of Harvard, the Massachusetts Institute of Technology, the Whitehead Institute, as well as Novartis' new research HQ and scores of smaller biotech companies. From its headquarters and facilities across the globe, Biogen Idec's marketed products reach patients in more than 90 countries worldwide. Biogen Idec is gaining a reputation as one of the leading biotechnology innovators, particularly in the fields of cancer and immunology. Compared to the other 'big pharma' players it is still relatively small and its marketing organisation lacks scope and maturity. Traditionally, Biogen Idec has sought out partners to achieve its marketing goals and it has done particularly well from its agreement with Roche/Genentech for Rituxan.The failure of the company to attract a takeover offer from the major pharmaceutical companies in 2007, means that Biogen Idec will remain an independent company for the time being. Potential bidders may have been put off by the escalating share price, or the risky bet on Biogen Idec and Elan's multiple sclerosis drug, Tysabri, following its linking to a rare brain infection that could reduce the drug's market potential. The successful re-launch and uptake of Tysabri may go some way to allay these fears. Of its key products, Avonex remains the main growth driver alongside Rituxan, supported by the re-launch of Tysabri for multiple sclerosis (MS).The group's core asset is its strong pipeline of middle- to late-stage drugs. The pipeline contains some promising line-extensions and biologics for lymphoma, leukaemia and immune disease such as MS, Crohn's disease and rheumatoid arthritis. Of particular note are lumiliximab, which could be the next new medication for chronic lymphocytic leukaemia, galiximab for non-Hodgkin's lymphoma, lixivaptan for heart failure, BG-12 for MS and ocrelizumab, which has the potential to take over from Rituxan in rheumatoid arthritis as well as being used in combination with Rituxan for MS.These projects may yet make an attractive proposition to any potential suitors, however, should Biogen Idec go it alone, then it will need to enhance its in-house sales and marketing capabilities to successfully bring these to the widest possible market, allowing it to take on more responsibility for its own destiny and to ensure it can achieve organic growth without relying on other potentially competitive companies.

1. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Biogen Idec: Pipeline ' Products ' Performance ' Potential
Published on January 2010
Report Summary
Pharmaceutical company intelligence reports from Espicom provide a full review of the company's activities together with five-year
sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete
analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and
divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of
the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices
provide more in-depth information on financials, agreements and corporate events. Biogen Idec is a global research-based company
focused on the development, manufacture and commercialisation of novel therapeutics for human health care. Biogen Idec's
headquarters in Cambridge, MA, is strategically close to the renowned research institutions of Harvard, the Massachusetts Institute of
Technology, the Whitehead Institute, as well as Novartis' new research HQ and scores of smaller biotech companies. From its
headquarters and facilities across the globe, Biogen Idec's marketed products reach patients in more than 90 countries worldwide.
Biogen Idec is gaining a reputation as one of the leading biotechnology innovators, particularly in the fields of cancer and
immunology. Compared to the other 'big pharma' players it is still relatively small and its marketing organisation lacks scope and
maturity. Traditionally, Biogen Idec has sought out partners to achieve its marketing goals and it has done particularly well from its
agreement with Roche/Genentech for Rituxan.
The failure of the company to attract a takeover offer from the major pharmaceutical companies in 2007, means that Biogen Idec will
remain an independent company for the time being. Potential bidders may have been put off by the escalating share price, or the risky
bet on Biogen Idec and Elan's multiple sclerosis drug, Tysabri, following its linking to a rare brain infection that could reduce the drug's
market potential. The successful re-launch and uptake of Tysabri may go some way to allay these fears.
Of its key products, Avonex remains the main growth driver alongside Rituxan, supported by the re-launch of Tysabri for multiple
sclerosis (MS).
The group's core asset is its strong pipeline of middle- to late-stage drugs. The pipeline contains some promising line-extensions and
biologics for lymphoma, leukaemia and immune disease such as MS, Crohn's disease and rheumatoid arthritis. Of particular note are
lumiliximab, which could be the next new medication for chronic lymphocytic leukaemia, galiximab for non-Hodgkin's lymphoma,
lixivaptan for heart failure, BG-12 for MS and ocrelizumab, which has the potential to take over from Rituxan in rheumatoid arthritis as
well as being used in combination with Rituxan for MS.
These projects may yet make an attractive proposition to any potential suitors, however, should Biogen Idec go it alone, then it will
need to enhance its in-house sales and marketing capabilities to successfully bring these to the widest possible market, allowing it to
take on more responsibility for its own destiny and to ensure it can achieve organic growth without relying on other potentially
competitive companies.
Table of Content
Biogen Idec: Pipeline ' Products ' Performance ' Potential Page 1/6

2. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Contents
Latest Results... 2
EXEC UTIVE SUMMARY.5
Introduction..... 5
Current Financial Position.... 6
Company Performance .....6
Business Segment Performance....6
Geographic Segment Performance.....8
Company Strategy 11
R&D Strategy11
Mergers, Acquisitions and Divestitures...12
Key Agreements. 13
Production... 13
Employees.... 13
Product Performance Forecasts ...... 14
Pipeline Analysis... 16
Discontinued R&D Projects16
Other Factors Affecting the Bottom Line...... 17
Conclusions/Outlook... 18
THERAPEUTIC AREA FOC US.....21
R&D PIPELINE ......22
ONCO LOG Y ..23
Marketed Products......23
Rituxan...23
R&D Projects... 31
BIIB021...31
BIIB022...31
GA101.....31
Galiximab.....32
Lumiliximab32
Volociximab34
Growth Forecast ... 35
CEN TRAL NE RVOUS SYSTEM...36
Marketed Products...... 36
Avonex...36
Tysabri....39
R&D Projects...44
BIIB014...44
BG-12......44
Daclizumab.45
Fampridine-SR...46
Neublastin...47
PEGylated Interferon beta-1a (PEG IFN).....47
Growth Forecast....48
IMMUNO LOG Y....49
Marketed Products......49
Fumaderm ..49
Rituxan...50
R&D Projects...56
Biogen Idec: Pipeline ' Products ' Performance ' Potential Page 2/6

3. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Anti-TWEAK.56
Ocrelizumab56
Growth Forecast....58
OTHERS..59
R&D Projects... 59
Adentri...59
Aviptadil60
FIX:Fc......60
Lixivaptan....60
Long-acting recombinant Factor VIII..60
APPENDI X 1 - FIN ANCI AL PERFORMANCE ...63
Full Year Results 2008.. 63
APPENDI X 2 - KEY CO RPORATE EVEN TS......66
APPENDI X 3 - KEY AGREE MEN TS...67
Alnylam Pharmaceuticals Inc...67
Amorfix Life Sciences Ltd...67
Astellas Pharma68
Bayer ......68
Biovitrum AB......68
Brain Science Institute, Johns Hopkins University 68
Cardiokine Biopharma LLC69
Cell Therapeutics Inc.....69
Celltech Group Plc...70
Chemical Diversity Labs Inc......70
Dyax Corp....70
Fumedica GmbH.....70
Genaissance Pharmaceuticals Inc..71
Gene Network Sciences Inc......71
GlycoFi Inc...71
ImmunoGen Inc71
Lexicon Genetics Inc.....72
Merck & Co..72
mondoBIOTECH AG72
MorphoSys AG..72
NeoGenesis Pharmaceuticals Inc...73
Neurimmune SubOne AG..73
PDL BioPharma Inc/Ophthotech Corp73
Pharmaceutical Product Development Inc (PPD) 73
Rentschler Biotechnologie GmbH 74
Roche.....74
Sunesis Pharmaceuticals Inc ....75
Tanox Inc......76
The Medicines Company....76
UCB .76
Vernalis Plc...76
Xenogen Corp...77
Biogen Idec: Pipeline ' Products ' Performance ' Potential Page 3/6

4. Find Industry reports, Company profiles
ReportLinker and Market Statistics
APPENDI X 4 - IN FRASTRUCTURE....78
Research and Development Facilities.... 78
Manufacturing Facilities..... 78
APPENDI X 5 - KEY PHARMACE UTIC AL
SUBSIDI ARIE S/JOIN T VEN TURES80
Subsidiaries....80
Joint Ventures80
APPENDI X 6 - PROD UCT INDE X......81
Index of Tables
Principal Operating Results......1
Sales By Business Segment......7
Sales By Geographic Area..8
Product Sales By Geographic Area..9
Long-Term Assets By Geographical Area....10
Recent Product Approvals......15
Major Therapeutic Areas And Sales.....21
Major Oncology Products, 2008...23
Major Central Nervous System Products, 2008..36
Major Immunology Products, 2008....49
Index of Charts
Sales By Business Area......7
Sales By Geographic Area..8
Product Sales By Geographic Area..9
Long-Term Assets By Geographical Area....10
Sales of Top 4 Products (2003A-2013E)15
Sales of Top Products, 2008...15
Rituxan Sales (2003A-2013E).27
Avonex Sales (2003A-2012E).38
Tysabri Sales (2003A-2013E)..43
Rituxan Sales (2002A-2012E).54
Ocrelizumab Sales (2011E-2015E).57
Sales, Costs and Operating Income..... 64
Profitability and Research Ratios. 64
R&D Expenditure and Capital Expenditure 64
Current Assets, Liabilities and Ratio.....65
Assets, Cash and Liquidity......65
Employees and Productivity...65
Biogen Idec: Pipeline ' Products ' Performance ' Potential Page 4/6

5. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact
Order Information
Please verify that the product information is correct and select the format(s) you require.
Biogen Idec: Pipeline ' Products ' Performance ' Potential
Product Formats
Please select the product formats and the quantity you require.
Digital Copy--USD 1 040.00 Quantity: _____
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title: Mr Mrs Dr Miss Ms Prof
First Name: _____________________________ Last Name: __________________________________
Email Address: __________________________________________________________________________
Job Title: __________________________________________________________________________
Organization: __________________________________________________________________________
Address: __________________________________________________________________________
City: __________________________________________________________________________
Postal / Zip Code: __________________________________________________________________________
Country: __________________________________________________________________________
Phone Number: __________________________________________________________________________
Fax Number: __________________________________________________________________________
Biogen Idec: Pipeline ' Products ' Performance ' Potential Page 5/6

6. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.
Payment by credit card Card Number: ______________________________________________
Expiry Date __________ / _________
CVV Number _____________________
Card Type (ex: Visa, Amex…) _________________________________
Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189
Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE
Customer signature:
Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms
Please fax this form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
Biogen Idec: Pipeline ' Products ' Performance ' Potential Page 6/6